Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Kurma Partners

Investor type Venture Capital
Founders Thierry Laugel

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 90
Average round size
info
The average size of a deal this fund participated in
$25M
Portfolio companies 51
Rounds per year 6.92
Lead investments 27
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.43
Exits 9
Key employees 8
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Pharmaceutical
  • Therapeutics
Summary

In 2009 was created Kurma Partners, which is appeared as VC. The venture was found in Europe in France. The main office of represented VC is situated in the Paris.

The fund was created by Thierry Laugel. The overall number of key employees were 6.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Kurma Partners, startups are often financed by Ysios Capital, Wilco, Bpifrance. The meaningful sponsors for the fund in investment in the same round are Paris-Saclay Seed Fund, Bpifrance, Idinvest Partners. In the next rounds fund is usually obtained by Bpifrance, Life Sciences Partners, Ysios Capital.

The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year. The higher amount of exits for fund were in 2018. Comparing to the other companies, this Kurma Partners performs on 19 percentage points less the average number of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 54 percentage points more often commits exit comparing to other organizations.

The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - France. Among the most successful fund investment fields, there are Therapeutics, Medical Device. Among the most popular portfolio startups of the fund, we may highlight AM Pharma, Minoryx Therapeutics, Dynacure.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Kurma Partners:
Typical Co-investors
Kurma Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Kurma Partners:

Funds with similar focus

Funds from France
Funds with similar focus located in France:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Ganymed Robotics

Robotics
$24M07 Jul 2022 Paris, Ile-de-France, France

Charles.co

Fitness
Health Care
Wellness
$8M30 Jun 2022 Paris, Ile-de-France, France

ImCheck Therapeutics

Biopharma
Biotechnology
Health Care
Life Science
Therapeutics
$113M13 Jun 2022 Marseille, Provence-Alpes-Côte d'Azur, France

Germitec S.A.

Health Care
Medical
$12M10 May 2022 Ivry-sur-seine, Ile-de-France, France

DAMAE Medical

Biotechnology
Health Care
Medical
Medical Device
$5M03 Feb 2022 Paris, Ile-de-France, France

NaoX Technologies

Fitness
Health Care
$5M27 Jan 2022 France, Ile-de-France, France

Sunrise

Health Care
Lifestyle
Medical Device
Wellness
$7M15 Dec 2021 Brussels, Brussels Hoofdstedelijk Gewest, Belgium

Corteria Pharmaceuticals

Pharmaceutical
Therapeutics
$14M09 Dec 2021 Paris, Ile-de-France, France

Emergence Therapeutics

Fitness
Health Care
Wellness
$102M07 Dec 2021 Duisburg, Nordrhein-Westfalen, Germany
News
Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Kurma Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: